Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $832.8 million.

  • BeOne Medicines' Non-Current Debt rose 34410.52% to $832.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $832.8 million, marking a year-over-year increase of 34410.52%. This contributed to the annual value of $166.5 million for FY2024, which is 1575.46% down from last year.
  • As of Q3 2025, BeOne Medicines' Non-Current Debt stood at $832.8 million, which was up 34410.52% from $146.1 million recorded in Q2 2025.
  • BeOne Medicines' Non-Current Debt's 5-year high stood at $832.8 million during Q3 2025, with a 5-year trough of $146.1 million in Q2 2025.
  • Its 5-year average for Non-Current Debt is $225.6 million, with a median of $199.0 million in 2024.
  • The largest annual percentage gain for BeOne Medicines' Non-Current Debt in the last 5 years was 34410.52% (2025), contrasted with its biggest fall of 2114.74% (2025).
  • BeOne Medicines' Non-Current Debt (Quarter) stood at $202.1 million in 2021, then increased by 3.48% to $209.1 million in 2022, then dropped by 5.51% to $197.6 million in 2023, then dropped by 15.75% to $166.5 million in 2024, then soared by 400.2% to $832.8 million in 2025.
  • Its last three reported values are $832.8 million in Q3 2025, $146.1 million for Q2 2025, and $160.2 million during Q1 2025.